Abstract:Background: B cells can function as antigen-presenting cells by presenting antigens captured by the B-cell receptor (BCR) on Class II Major Histocompatibility Complex (MHC II) to T cells. In addition, B-cells can also maintain immune homeostasis by expressing PD-L1 and suppressing T-cell activity. Epstein-Barr virus (EBV) infection can disrupt B-cell function and lead to B cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Here we show that EBV-positive DLBCL (EBV+ DLBCL) has decreased expression of BCR and MHC II, but over-expressed PD-L1, which may lead to immune evasion. Methods: An EBV+ DLBCL cohort (n = 30) and an EBV- DLBCL control cohort (n = 83) were established. Immunostaining of PD-L1, MHC II, MHC II Transactivator (CIITA) and pBTK was performed on automated stainer. H-score was used to denote the results of staining of PD-L1 and pBTK. Break apart and deletion of CIITA locus was studied by fluorescent in situ hybridization. Surface immunoglobulin mean fluorescent insensitivity (MFI) was detected by flow cytometry to demonstrate the level BCR. Results: EBV+ DLBCL showed significantly lower expression of CIITA and MHC II compared to EBV- DLBCL. Genetic aberrations involving CIITA were also more common in EBV+ DLBCL, with 23% break apart events and 6% deletion events, comparted to 2% break apart and 0% deletion in EBV- DLBCL. In addition to the loss of antigen presentation molecule, the antigen capture receptor, BCR, was also down-regulated in EBV+ DLBCL. Accordingly, BCR signaling was also significantly decreased in EBV+ DLBCL as denoted by the respective pBTK levels. Conclusions: EBV+ DLBCL shows over expression of the T-cell inhibitory ligand, PD-L1. Antigen capture and presentation system were disrupted, and T-cell inhibitory molecule was hijacked in EBV+ DLBCL, which may contribute to immune escape in this high risk disease. Therapies targeting these aberrations may improve the outcome of patients with EBV+ DLBCL.

Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.

B7-H4 is highly expressed in aggressive Epstein-Barr virus positive diffuse large B-cell lymphoma and inhibits apoptosis through upregulating Erk1/2 and Akt signalling pathways

Expression of B7-H4 protein and its relationship with clinical characteristics in diffuse large B-cell lymphoma

[Prognostic Significance of Proteins Expression by Immunohistochemical Method in Diffuse Large B Cell Lymphoma].

B7-H4 expression in various tumors determined using a novel developed monoclonal antibody

EBV-positive Diffuse Large B-cell Lymphoma Features PD-L1 Protein but Not Mrna Overexpression.

Expression of the immune checkpoint molecules PD‑L1 and PD‑1 in EBV‑associated lymphoproliferative disorders: A meta‑analysis

The Expression Of B7-H4 In Serum And Lymphoma Tissues And Its Clinical Significance

B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunity

Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma Features Disrupted Antigen Capture/presentation and Hijacked T-cell Suppression

B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma

[Expression of B7-H4 in Prostate Cancer and Its Clinical Significance].

Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.

Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact

B7-H6 is Associated with Poor Prognosis and a Potential Therapeutic Target of T-Lymphoblastic Lymphoma

Aberrant Expression of B7-H4 and BTLA in Tumor Model

B7-H4 Correlates with Clinical Outcome and Immunotherapeutic Benefit in Muscle-Invasive Bladder Cancer

Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer

B7-H6 is a New Potential Biomarker and Therapeutic Target of T-lymphoblastic Lymphoma

The Expression of Three Negative Co-Stimulatory B7 Family Molecules in Small Cell Lung Cancer and Their Effect on Prognosis

Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.